N-isopentyl-thioformamide | 873974-70-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硫代羧酸及其衍生物
• 英文名称: N-isopentyl-thioformamide
• 英文别名: N-Isopentyl-thioformamid；Thioameisensaeure-isopentylamid；N-(3-methylbutyl)methanethioamide
• CAS: 873974-70-0
• 化学式: C₆H₁₃NS
• mdl: MFCD19219511
• 分子量: 131.242
• InChiKey: CCJKXSVCYRTWKC-UHFFFAOYSA-N

物化性质

• 沸点：
  143-146 °C(Press: 10 Torr)
• 密度：
  0.924±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  44.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-isopentyl-thioformamide 、 2-溴苯乙酮 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Todd et al., Journal of the Chemical Society, 1937, p. 361,363

  摘要：

  DOI：
• 作为产物：
  描述：

  异戊胺 、 硫代甲酰胺 在 乙醇 作用下， 生成 N-isopentyl-thioformamide
  参考文献：
  名称：

  Thioformamide compounds

  摘要：

  公开号：

  US02265212A1

文献信息

• PYRAZOLE-3-CARBOXYLIC ACID AMIDE DERIVATIVE AND PEST CONTROL AGENT
  申请人：KUMIAI CHEMICAL INDUSTRY CO., LTD.

  公开号：US20200199096A1

  公开（公告）日：2020-06-25

  Embodiments provide a harmful organism control agent containing a pyrazole-3-carboxylic acid amide derivative or a salt thereof as an active ingredient, having an excellent harmful organism controlling effect. A pyrazole-3-carboxylic acid amide derivative represented by general formula [I]: (wherein, R 1 , R 2 , R 3 , R 4 , and R 5 represent a hydrogen atom, halogen atom, C 1 -C 6 alkyl group or the like, R 6 represents a C 1 -C 12 alkyl group, C 1 -C 12 haloalkyl group or the like, R 7 and R 8 represent a hydrogen atom, C 1 -C 12 alkyl group or the like) or an agriculturally acceptable salt thereof, and a harmful organism control agent containing the pyrazole-3-carboxylic acid amide derivative or an agriculturally acceptable salt thereof as an active ingredient.

  实施例提供了一种含有吡唑-3-羧酸酰胺衍生物或其盐作为活性成分的有害生物控制剂，具有出色的有害生物控制效果。一种由通式[I]表示的吡唑-3-羧酸酰胺衍生物：（其中，R1、R2、R3、R4和R5代表氢原子、卤原子、C1-C6烷基或类似物，R6代表C1-C12烷基、C1-C12卤代烷基或类似物，R7和R8代表氢原子、C1-C12烷基或类似物）或其农业可接受的盐，以及一种含有吡唑-3-羧酸酰胺衍生物或其农业可接受的盐作为活性成分的有害生物控制剂。
• Benzopyran derivatives, method of production and use thereof
  申请人：Sebille Sophie

  公开号：US20070112063A1

  公开（公告）日：2007-05-17

  The invention relates to novel benzopyran derivatives of formula I, to their method of production, to composition comprising the derivatives and use thereof. wherein: R 1 , R 2 , R 3 and R 4 are independently hydrogen, halogen, C 1-6 -alkyl, C 3-8 -cycloalkyl, hydroxy, C 1-6 -alkoxy, C 1-6 -alkoxy-C 1-6 -alkyl, nitro, amino, cyano, cyanomethyl, perhalomethyl, C 1-6 -monoalkyl- or dialkylamino, sulfamoyl, C 1-6 -alkylthio, C 1-6 -alkylsulfonyl, C 1-6 -alkylsulfinyl, formyl, C 1-6 -alkylcarbonylamino, R 8 arylthio, R 8 arylsulfinyl, R 8 arylsulfonyl, C 1-6 -alkoxycarbonyl, C 1-6 -alkoxycarbonyl-C 1-6 -alkyl, carbamoyl, carbamoylmethyl, C 1-6 -monoalkyl- or dialkylaminocarbonyl, C 1-6 -monoalkyl- or dialkylaminothiocarbonyl, ureido, C 1-6 -monoalkyl- or dialkylaminocarbonylamino, thioureido, C 1-6 -monoalkyl- or dialkylaminothiocarbonylamino, C 1-6 -monoalkyl- or dialkylaminosulfonyl, carboxy, carboxy-C 1-6 -alkyl, acyl, R 8 aryl, R 8 aryl-C 1-6 -alkyl, R 8 aryloxy; R 5 and R 6 are each independently hydrogen, C 1-6 -alkyl or, R 5 and R 6 taken together with the carbon atom to which they are attached form a 3- to 6-membered carbocyclic ring; R 7 is 2-, 3- or 4-pyridyl optionally mono- or polysubstituted by R 1 ; R 7 is 2- or 3-thienyl optionally mono- or polysubstituted substituted by R 1 or R 7 is phenyl optionally mono- or polysubstituted by R 1 with the exception of or R 7 representing C 6 H 5 ; R 8 is hydrogen, halogen, C 1-6 -alkyl, C 3-8 -cycloalkyl, hydroxy, C 1-6 -alkoxy, nitro, amino, cyano, cyanomethyl, perhalomethyl; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture or any polymorphic and tautomeric form.

  本发明涉及式I的新型苯并吡喃衍生物，其制备方法，包含这些衍生物的组合物以及它们的用途。其中：R1、R2、R3和R4独立地表示氢、卤素、C1-6烷基、C3-8环烷基、羟基、C1-6烷氧基、C1-6烷氧基-C1-6烷基、硝基、氨基、氰基、氰甲基、多卤甲基、C1-6单烷基或二烷基氨基、磺酰氨基、C1-6烷基硫醇基、C1-6烷基磺酰基、C1-6烷基亚磺酰基、甲酰基、C1-6烷基羰基氨基、R8芳基硫基、R8芳基亚磺酰基、R8芳基磺酰基、C1-6烷氧羰基、C1-6烷氧羰基-C1-6烷基、氨基甲酰基、氨基甲基、C1-6单烷基或二烷基氨基羰基、C1-6单烷基或二烷基氨基硫氧基、尿素基、C1-6单烷基或二烷基氨基羰基氨基、硫脲基、C1-6单烷基或二烷基氨基硫脲基、C1-6单烷基或二烷基氨基磺酰基、羧基、羧基-C1-6烷基、酰基、R8芳基、R8芳基-C1-6烷基、R8芳氧基；R5和R6各自独立地表示氢、C1-6烷基或者R5和R6结合到它们所连接的碳原子上形成3-6成员的碳环；R7是2-、3-或4-吡啶基，可选地被R1单或多取代；R7是2-或3-噻吩基，可选地被R1单或多取代，或者R7是苯基，可选地被R1单或多取代，但不包括R7代表C6H5；R8表示氢、卤素、C1-6烷基、C3-8环烷基、羟基、C1-6烷氧基、硝基、氨基、氰基、氰甲基、多卤甲基或其药学上可接受的酸或碱盐，或任何光学异构体或光学异构体混合物，包括外消旋混合物或任何多态和互变异构体。
• SORBEFACIENTS
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP0966973A1

  公开（公告）日：1999-12-29

  Pharmaceutical compositions for improving the absorption of drugs having poor absorbability in the digestive tract. The compositions contain drugs and anion exchange resins and show excellent absorbability in the digestive tract.

  药物组合物，用于提高消化道内吸收性差的药物的吸收。该组合物包含药物和阴离子交换树脂，能够在消化道内表现出极佳的吸收性。
• MEDICINAL COMPOSITION FOR PERCUTANEOUS ADMINISTRATION
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1043020A1

  公开（公告）日：2000-10-11

  A percutaneously absorbable medicinal composition comprising a percutaneous absorption enhancer and at least one member selected from the group consisting of aromatic amidine derivatives represented by formula (1): salts of the derivatives, solvates of the derivatives, and solvates of salts of the derivatives. The present invention provides a composition which exhibits high percutaneous absorbability, which can maintain an effective blood level for prolonged periods of time, which provides antithrombotic and anticoagulant effects.

  一种经皮吸收的药物组合物，包括经皮吸收增强剂以及选择自式（1）所表示的芳香族酰胺衍生物的至少一种成员：衍生物的盐，衍生物的溶剂，以及衍生物的盐的溶剂。本发明提供了一种组合物，具有高经皮吸收性，可以维持有效的血液水平长时间，具有抗血栓和抗凝血作用。
• NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0798295A1

  公开（公告）日：1997-10-01

  An amidinonaphthyl derivative represented by the following general formula (I) which has a platelet aggregation inhibiting action based on the activated blood coagulation factor X inhibiting action and is useful as an anti-thrombus agent and the like, a salt thereof, an intermediate thereof and a pharmaceutical composition which comprises the amidinonaphthyl derivative. An amidinonaphthyl derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. (symbols in the formula have the following meanings; R1: a hydrogen atom or a group represented by the formula -A-W-R4, A: a group represented by the formula a group represented by the formula or a group represented by the formula -SO2-, X: an oxygen atom or a sulfur atom, W: a single bond or a group represented by the formula -NR5-, R4: a hydroxyl group, a lower alkoxy group, etc., not a hydroxyl group or a lower alkoxy group, R5: a hydrogen atom, a carbamoyl group, a lower alkoxycarbonyl group, etc., R2: a lower alkyl group, R3: a hydrogen atom, a halogen atom, a carboxyl group, B: a lower alkylene group or a carbonyl group, and n: 0 or 1).

  一种由下式通式（I）表示的脒基萘衍生物、其盐、中间体和包含该脒基萘衍生物的药物组合物，该脒基萘衍生物具有基于活化血液凝固因子 X 抑制作用的血小板聚集抑制作用，可用作抗血栓剂等。 由以下通式（I）代表的脒基萘衍生物或其药学上可接受的盐。 (式中符号含义如下； R1：氢原子或由式-A-W-R4 所代表的基团、 A：由式 式所代表的基团 或由式 -SO2- 代表的基团、 X：氧原子或硫原子，W：单键或由式-NR5-代表的基团，R4：羟基、低级烷氧基等，不是羟基或低级烷氧基，R5：氢原子、氨基甲酰基、低级烷氧基羰基等，R2：低级烷基，R3：氢原子、卤素原子、羧基，B：低级亚烷基或羰基，n：0 或 1）。